DPP-4
Read More about this categoryShow Less
Dipeptidyl peptidase-4 (DPP-4), originally identified in 1966 as a dipeptide naphthylamidase hydrolyzing glycyl-prolyl-beta-naphthylamide, is a membrane-associated peptidase that selectively cleaves the N-terminal penultimate proline or alanine amino acids. The most common substrates of DPP-4 include glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2), peptide YY, neuropeptide, chemokine ligand 12/stromal-derived factor-1 (CXCL12/SDF-1) and substance P. DPP-4, as a type II cell surface protein and a soluble form, has been found to be widely distributed in organs (such as the bone marrow, the lung, spleen, liver, pancreas, kidney and intestines) and body fluids (such as serum/plasma, cerebrospinal fluid, synovial fluid and semen). Besides its peptidase activity, DPP-4 has been found to be associated with immune stimulation, extracellular matrix degradation, lipid accumulation and resistance to anticancer agents.
Products Related to DPP-4(18)
- GC12895SaxagliptinCAS: 361442-04-8Purity: >99.50%
Saxagliptin is a highly potent dipeptidyl peptidase-4 (DPP-4) inhibitor that regulates blood glucose by selectively inhibiting the DPP-4 enzyme, thereby elevating levels of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
- GC10104GlimepirideCAS: 93479-97-1Purity: >98.00%
Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin. Glimepiride is used for the treatment of type 2 diabetes mellitu as monotherapy as well as in combination with metformin or insulin.
- GC14786P32/98 (hemifumarate)CAS: 251572-86-8Purity: >98%
competitive transition-state substrate analog inhibitor of DPP IV
- GC10018Talabostat mesylateCAS: 150080-09-4Purity: >99.00%
Talabostat (PT100) is an orally active and non-selective inhibitor of dipeptidyl peptidase IV (DPP-IV) ( IC 50 < 4 nM; K i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) ( IC 50 = 560 nM), inhibiting DPP 8/9 ( IC 50 = 4/11 nM; K i = 1.5/0.76 nM), prolyl endopeptidase (QPP) (IC50= 310 nM), DPP2, and other DASH family enzymes.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC12895 | Saxagliptin | 361442-04-8 | >99.50% | |
Saxagliptin is a highly potent dipeptidyl peptidase-4 (DPP-4) inhibitor that regulates blood glucose by selectively inhibiting the DPP-4 enzyme, thereby elevating levels of endogenous glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). | ||||
| GC10104 | Glimepiride | 93479-97-1 | >98.00% | |
Glimepiride is a second-generation sulfonylurea that stimulates pancreatic β cells to release insulin. Glimepiride is used for the treatment of type 2 diabetes mellitu as monotherapy as well as in combination with metformin or insulin. | ||||
| GC10298 | Sitagliptin phosphate monohydrate | 654671-77-9 | >99.50% | |
| GC10802 | K 579 | 440100-64-1 | >98% | |
| GC12235 | Sitagliptin (phosphate) | 654671-78-0 | >98.00% | |
DPP-4 inhibitor | ||||
| GC12603 | DPPI 1c hydrochloride | 866396-34-1 | >98% | |
A DPP-4 inhibitor | ||||
| GC13949 | Alogliptin Benzoate | 850649-62-6 | >99.50% | |
A DPP-4 inhibitor | ||||
| GC14126 | NVP DPP 728 dihydrochloride | 247016-69-9 | >98% | |
| GC14201 | PK 44 phosphate | 1017682-65-3 | >98% | |
DPP-IV inhibitor | ||||
| GC14786 | P32/98 (hemifumarate) | 251572-86-8 | >98% | |
competitive transition-state substrate analog inhibitor of DPP IV | ||||
| GC14827 | Linagliptin (BI-1356) | 668270-12-0 | >99.50% | |
A potent DPP-4 inhibitor | ||||
| GC15130 | Alogliptin (SYR-322) | 850649-61-5 | >99.00% | |
| GC15576 | Teneligliptin hydrobromide | 906093-29-6 | >99.50% | |
A DPP-4 inhibitor | ||||
| GC16613 | Trelagliptin | 865759-25-7 | >99.50% | |
A DDP-4 inhibitor | ||||
| GC16733 | Vildagliptin (LAF-237) | 274901-16-5 | >98.00% | |
A DPP-4 inhibitor | ||||
| GC17012 | MK3102 | 1226781-44-7 | >99.00% | |
MK3102 (Omarigliptin) is a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor (IC50: 2.2 nM) developed for the treatment of type 2 diabetes. | ||||
| GC17479 | Trelagliptin succinate | 1029877-94-8 | >99.50% | |
A DDP-4 inhibitor | ||||
| GC10018 | Talabostat mesylate | 150080-09-4 | >99.00% | |
Talabostat (PT100) is an orally active and non-selective inhibitor of dipeptidyl peptidase IV (DPP-IV) ( IC 50 < 4 nM; K i = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) ( IC 50 = 560 nM), inhibiting DPP 8/9 ( IC 50 = 4/11 nM; K i = 1.5/0.76 nM), prolyl endopeptidase (QPP) (IC50= 310 nM), DPP2, and other DASH family enzymes. | ||||